Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/BB1BC6F233AD2FD04688C16C709FF5FCE4890F8B80E2C1836F45360AF631C337E985DF981F25D3F2A931A1EF6E209FE0http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/BB1BC6F233AD2FD04688C16C709FF5FCE4890F8B80E2C1836F45360AF631C337E985DF981F25D3F2A931A1EF6E209FE0http://www.w3.org/2000/01/rdf-schema#comment"For higher-risk myelodysplastic syndrome (MDS) patients EVI1-high patients have poorer survival rate compared with EVI1-low patients. Moreover EVI1-high was an adverse prognostic marker for MDS with excess blasts subtype. Taken together EVI1 overexpression is a poor prognostic marker for higher-risk MDS group and could be included in risk stratification for MDS patients."xsd:string
http://purl.uniprot.org/uniprot/#_BC68E7621F447A7B196766584725E944E1281B64B6B110AF0D8A6AF098760136F811000859D9DD7E1D7E2971AA1525DEhttp://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/BB1BC6F233AD2FD04688C16C709FF5FCE4890F8B80E2C1836F45360AF631C337E985DF981F25D3F2A931A1EF6E209FE0
http://purl.uniprot.org/uniprot/A0A0C3SFZ7http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/BB1BC6F233AD2FD04688C16C709FF5FCE4890F8B80E2C1836F45360AF631C337E985DF981F25D3F2A931A1EF6E209FE0
http://purl.uniprot.org/uniprot/#_A0A0C3SFZ7-mappedCitation-29846125http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/BB1BC6F233AD2FD04688C16C709FF5FCE4890F8B80E2C1836F45360AF631C337E985DF981F25D3F2A931A1EF6E209FE0